Anirvan Ghosh - 09 Feb 2022 Form 4 Insider Report for Unity Biotechnology, Inc. (UBX)

Role
Chief Executive Officer, Director
Signature
/s/ Anirvan Ghosh
Issuer symbol
UBX
Transactions as of
09 Feb 2022
Transactions value $
$0
Form type
4
Filing time
15 Feb 2022, 16:12:26 UTC
Previous filing
28 Jun 2021
Next filing
15 Mar 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction UBX Common Stock, $0.0001 par value Award $0 +142K +15.37% $0.00 1.06M 09 Feb 2022 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction UBX Stock Option (Right to Buy) Award $0 +567K $0.00 567K 09 Feb 2022 Common Stock 567K $1.06 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents Restricted Stock Units ("RSUs") one third of which vests on February 9, 2023 with the remaining RSUs vesting in equal quarterly installments over a two year period thereafter. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer.
F2 Includes RSUs which vest over time measured from the grant date.
F3 The underlying shares vest and become exercisable pursuant to the following schedule: One Third of the shares subject to the option vest on February 9, 2023 (the "Vesting Commencement Date"), and the remaining shares subject to the option vest in 24 successive, equal monthly installments thereafter on each monthly anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date.